8-azaprostaglandin derivative compound and agent comprising the compound as active ingredient

An 8-azaprostaglandin derivative compound represented by formula (I-a1-2):

• wherein Ya is —S— or —SO2—;
• ring 6 is 5- or 6-membered mono-heterocyclic aryl containing hetero atoms selected from 1 to 4 nitrogen, 1 to 2 oxygen, and 1 to 2 sulfur atoms which may be partially or fully saturated;
• R100 is hydrogen atom or C1-4 alkyl;
• R12 is (1) a hydrogen atom, (2) C1-10 alkyl or (3) C2-10 acyl;
• U3 is (1) C1-8 alkyl optionally substituted by 1 to 3 substituent(s) selected from C1-10 alkyl, halogen, hydroxy, alkoxy, alkylthio and NR13R14, (2) C2-8 alkenyl optionally substituted by 1 to 3 substituent(s) selected from C1-10 alkyl, halogen, hydroxyl, alkoxy, alkylthio and —NR13R14, (3) C2-8 alkynyl optionally substituted by 1 to 3 substituent(s) selected from C1-10 alkyl, halogen, hydroxy, alkoxy, alkylthio and —NR13R14, (4) C1-8 alkyl substituted by ring4 or (5) ring4,
• R13 and R14 are, each independently, (1) a hydrogen atom or (2) C1-10 alkyl, ring4 may be substituted by 1 to 5 R,
• R is (1) C1-10 alkyl, (2) C2-10 alkenyl, (3) C2-10 alkynyl, (4) C1-10 alkoxy, (5) C1-10 alkylthio, (6) halogen, (7) hydroxy, (8) nitro, (9) —NR15R16, (10) C1-10 alkyl substituted by C1-10 alkoxy, (11) C1-10 alkyl substituted by 1 to 3 halogen atom(s), (12) C1-10 alkyl substituted by C1-10 alkoxy substituted by 1 to 3 halogen atom(s), (13) C1-10 alkyl substituted by —NR15R16, (14) ring5, (15) —O-ring5, (16) C1-10 alkyl substituted by ring5, (17) C2-10 alkenyl substituted by ring5, (18) C2-10 alkynyl substituted by ring5, (19) C1-10 alkoxy substituted by ring5, (20) C1-10 alkyl substituted by —O-ring5, (21) COOR17, (22) C1-10 alkoxy substituted by 1 to 4 halogen atom(s), (23) formyl, (24) C1-10 alkyl substituted by hydroxy or (25) C2-10 acyl,
• R15, R16 and R17 are, each independently, (1) a hydrogen atom or (2) C1-10 alkyl,
• ring5 may be substituted by 1 to 3 substituent(s) selected from following (1)-(9):
• (1) C1-10 alkyl, (2) C2-10 alkenyl, (3) C2-10 alkynyl, (4) C1-10 alkoxy, (5) C1-10 alkyl substituted by C1-10 alkoxy, (6) halogen atom, (7) hydroxy, (8) C1-10 alkyl substituted by 1 to 3 halogen atom(s), and (9) C1-10 alkyl substituted by C1-10 alkoxy substituted by 1 to 3 halogen atom(s),
• ring4 and ring5 are, each independently,
• (1) C3-15 mono-, bi- or tri-carbocyclic aryl which may be partially or fully saturated or (2) 3- to 15-membered mono-, bi- or tri-heterocyclic aryl which may be partially or fully saturated and contains a hetero atom(s) selected from 1 to 4 nitrogen, 1 to 2 oxygen and 1 to 2 sulfur atom(s), or
• a pharmaceutically acceptable salt thereof.